NCT00709423 is a Phase 2 clinical trial of Moxaverine in Regional Blood Flow, sponsored by Medical University of Vienna.

Who is sponsoring NCT00709423?

NCT00709423 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT00709423?

Interventions in NCT00709423: Moxaverine, Moxaverin 150mg, NaCl.

What condition does NCT00709423 study?

NCT00709423 studies Regional Blood Flow, Ocular Physiology, Retina.

Is NCT00709423 still recruiting?

NCT00709423 is currently completed. Last updated 2 July 2008.

Last reviewed 2008-07-02 · How we verify

NCT00709423

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow

Completed Phase 2 Last updated 2 July 2008

What this trial tests

Phase 2 trial testing Moxaverine in Regional Blood Flow in 16 participants. Completed in 1 May 2007.

Timeline

1 March 2007

Primary endpoint
1 May 2007

1 May 2007

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	16
Start date	1 March 2007
Primary completion	1 May 2007
Estimated completion	1 May 2007
Sites	1 location across Austria

Drugs / interventions tested

Moxaverine (MOXAVERINE) — full drug profile →
Moxaverin 150mg — full drug profile →
NaCl — full drug profile →

Conditions studied

Regional Blood Flow — all drugs for Regional Blood Flow →
Ocular Physiology — all drugs for Ocular Physiology →
Retina — all drugs for Retina →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 35, any sex, with Regional Blood Flow or Ocular Physiology. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Retinal blood flow (Laser Doppler Velocimetry, Retinal Vessel Analyzer)
Time frame: 2 hours
Choroidal and optic nerve head blood flow (Laser Doppler Flowmetry)
Time frame: 2 hours

Sponsor's own description

A number of common eye diseases such as retinal artery and vein occlusion, diabetic retinopathy, age-related macular degeneration, glaucoma and anterior ischemic optic neuropathy are associated with ocular perfusion abnormalities. Although this is well recognized there is not much possibility to improve blood flow to the posterior pole of the eye in these diseases. Since many years, moxaverine is used in the therapy of perfusion abnormalities in the brain, the heart and the extremities. This is based on a direct vasodilator effect of the drug, but also on the rheological properties of red blood cells. Whether moxaverine affects blood flow in the eye is unknown. The present study aims to investigate whether moxaverine may improves blood flow in the eye after systemic administration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00709423 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 2 July 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00709423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing